Ko­di­ak turns down $125M pay­ment from Bak­er Bros. deal, slash­es roy­al­ty cap by 55%

4 years ago
Financing

EMA re­jects FDA-ap­proved Parkin­son's drug, signs off on Mod­er­na vac­cine use in ado­les­cents ahead of FDA

4 years ago
Pharma
FDA+

Jim Wil­son start­up Pas­sage Bio plugs in CFO, CMO; Till­man Gern­gross nabs a COO fa­mil­iar with Covid-19 fight at Pfiz­er ...

4 years ago
Peer Review

No­var­tis to pay near­ly $178M in law­suit over BRAF drug — and will be on the hook for roy­al­ty

4 years ago
Pharma

Covid-19 roundup: Pfiz­er to sup­ply US with 200M more vac­cines as UK study finds high­er an­ti­bod­ies in 8-10 week ...

4 years ago
Coronavirus

6 top drug­mak­ers of­fer per­spec­tives on FDA's new co­vari­ates in RCTs guid­ance

4 years ago
R&D
Pharma

Ad­verum faces murky fu­ture af­ter re­view turns up deep­er safe­ty is­sues for gene ther­a­py

4 years ago
R&D
Cell/Gene Tx

Bio­gen has a shaky end to H1 with a $542M write-off adding to its woes — but an­a­lysts see big rev­enue ahead for ...

4 years ago
Pharma

New da­ta show Bio­Mar­in's trou­bled he­mo­phil­ia gene ther­a­py con­tin­ues to fade, open­ing room for ri­vals

4 years ago
R&D

Seat­tle's Lu­men will move in­to new head­quar­ters in for­mer long-lived bak­ery amid tri­al ex­pan­sion

4 years ago
Manufacturing

US gov­ern­ment drops $200M in­to South African man­u­fac­tur­ing op­er­a­tion for Covid-19 vac­cines

4 years ago
Coronavirus
Manufacturing

Re­ci­pharm to con­struct new In­di­an fill-fin­ish fa­cil­i­ty as part of ex­ist­ing re­la­tion­ship with Nichep­harm found­ing ...

4 years ago
Outsourcing
Manufacturing

Covid-19 man­u­fac­tur­ing roundup: Mod­er­na inks deal for boost­er shots with Japan; Sput­nik Light could be man­u­fac­tured ...

4 years ago
Coronavirus
Manufacturing

Al­bireo re­veals $385K price tag for new­ly ap­proved pru­ri­tis drug; Jen­nifer Doud­na's Cari­bou up­sizes IPO

4 years ago
News Briefing

'By no means are we de­terred': Seres' stock spi­rals af­ter PhII mi­cro­bio­me fail in ul­cer­a­tive col­i­tis

4 years ago
R&D

Pfiz­er bets $1B cash on the orig­i­nal pro­tein de­graders as tech­nol­o­gy nears prime time

4 years ago
Deals

Bio­gen de­fends slow roll­out of new Alzheimer's drug, crit­i­cizes neg­a­tive me­dia at­ten­tion

4 years ago
Pharma

Mer­ck, Ei­sai notch full ap­proval for Keytru­da-TKI in­hibitor com­bo in ad­vanced en­dome­tri­al can­cer

4 years ago
Pharma
FDA+

Af­ter slic­ing and dic­ing TCRs for 8 years, Swedish biotech re­loads to an­gle for a spot in crowd­ed cell ther­a­py space

4 years ago
Financing
Cell/Gene Tx

Ex-Mer­ck chief Ken Fra­zier takes a lead­ing role in a $600M 'Health As­sur­ance' ven­ture fund

4 years ago
People

As part of move­ment to boost African pres­ence, Gri­fols to build IV bag fa­cil­i­ty in Nige­ria

4 years ago
Manufacturing

Catal­ent keeps adding on at key Ital­ian plant, this time with a pair of new biore­ac­tors and 100 jobs

4 years ago
Outsourcing
Manufacturing

Covid-19 roundup: Re­gen­eron asks FDA: Which gov­ern­ment agen­cies are track­ing vari­ants of con­cern?; Pfiz­er, ...

4 years ago
Coronavirus

Roche CEO Schwan puts 3-time Alzheimer's los­er gan­tenerum­ab back in the spot­light as FDA's con­tro­ver­sial Aduhelm OK ...

4 years ago
FDA+
First page Previous page 662663664665666667668 Next page Last page
A service from the Financial Times